ADARx Wins $535M In IPO And AbbVie Private Placement

With $535.2 million in combined gross proceeds now secured, ADARx Pharmaceuticals enters public markets carrying enough capital to advance its late-stage siRNA pipeline through process validation, manufacturing scale-up, and the regulatory submissions that follow. The San Diego-based company priced its Nasdaq IPO at $17.00 per share on September 24, 2026, with shares set to trade under the ticker ADRX from September 25.

The offering was upsized to 26,250,000 shares, generating approximately $446.3 million in gross proceeds before underwriting discounts and commissions. Underwriters retain a 30-day option to purchase up to an additional 3,937,500 shares at the public offering price, which could increase the IPO proceeds further. The offering is expected to close on September 28, 2026, subject to customary closing conditions.

The more operationally significant element for manufacturing and regulatory leads is AbbVie's concurrent private placement. AbbVie has agreed to purchase shares at the same $17.00 offering price, resulting in approximately a 4.9% stake in ADARx, capped at $100.0 million. That placement closes on the same date as the IPO, contingent on IPO consummation, and is structured as an exemption under the Securities Act of 1933. The stake positions AbbVie as a meaningful minority holder in a company whose siRNA platform will require GMP-compliant manufacturing infrastructure and validated delivery systems as programs advance toward pivotal trials.

For CMO partners and QA directors tracking the next-generation RNA therapeutics space, ADARx's capitalization signals that siRNA programs are moving closer to the scale-up decisions that trigger technology transfer agreements, analytical method validation, and supplier qualification under 21 CFR Part 211. The AbbVie relationship, while currently structured as a passive equity position, creates a visible pathway toward licensing or co-development arrangements that would carry their own GMP and supply-chain obligations.

J.P. Morgan, Morgan Stanley, TD Cowen, and UBS Investment Bank are acting as lead book-running managers; LifeSci Capital serves as book-running manager. Registration statements became effective with the SEC on September 24, 2026.

The underwriters' option exercise window, closing no later than late October 2026, represents the next measurable checkpoint for the total capital available to ADARx's development and manufacturing programs.

Source: GlobeNewswire via ADARx Pharmaceuticals press release, September 24, 2026.